Coşkun 2008.

Methods	A patient report of tactile and visual hallucinations with the combination of OROS methylphenidate and fluoxetine
Participants	Diagnosis of ADHD: DSM‐IV (subtype: combined) Age: 10 years old IQ: intellectual capacity within normal range Sex: male Ethnicity: Turkish Country: Turkey Comorbidity: oppositional defiant disorder, generalised and separation anxiety disorders Comedication: fluoxetine 10 mg/day MPH‐naïve: yes Sociodemographics: not stated
Interventions	OROS MPH 18 mg/day, comedication: fluoxetine, 10 mg/day OROS MPH 18 mg/day monotherapy, 2 weeks Treatment compliance: not stated
Outcomes	Non‐serious adverse events: Tactile and visual hallucinations. Worsening of previous sleep disturbance and decreased appetite
Notes	Funding/vested interests: the authors have no conflict of interest with any commercial or other associations, and no financial ties to disclose in connection with the submitted article Key conclusions of the study authors: here we report a paediatric patient who developed tactile and visual hallucinations with the combination of OROS methylphenidate and fluoxetine Comments from the study authors: in conclusion, we think that the causative agent was the combination of both medications rather than either medication alone. However, in either situation, it is important to note that this distressing side effect may occur even in the absence of underlying psychotic or substance‐related disorders, and clinicians' awareness is important in this issue, particularly in cases where polypharmacy is considered Supplemental information regarding ADHD diagnostic criteria, subtype of ADHD and ethnicity received through personal email correspondence with the authors in August 2013 (Coşkun 2013 [pers comm])